Preparation of siRNA encapsulated nanoliposomes suitable for siRNA delivery by simply discontinuous mixing.

In this study, we prepared nanoliposomes encapsulating siRNA by simply discontinuous mixing of lipids in ethanol/ether/water mixture and acidic siRNA solution without use of special equipment. The simple mixing siRNA/liposomal particles (siRNA/SMLs) prepared using ethanol/ether/water (3:1:1) mixture showed 120.4 ± 20.2 nm particle size, 0.174 ± 0.033 polydispersity and 86.5 ± 2.76% siRNA encapsulation rate. In addition, the SMLs almost completely protected the encapsulated siRNA from RNase A digestion. Coupling of anti-human epidermal growth factor receptor (EGFR) Fab' to siRNA/SMLs enhanced EGFR-specific cell penetration of SMLs and induced siRNA dependent gene silencing. Unexpectedly, the Cy5.5-labeled Fab' showed almost no in vivo targeting to the xenografted A549 tumors in SCID-NOD mice. However, multiple injection of the unmodified siRNA/SMLs accumulated in the tumors and induced siRNA-dependent in vivo gene silencing. These results demonstrate that the siRNA/SMLs can be used as a siRNA delivery tool for gene therapy. PMID: 29501600 [PubMed - as supplied by publisher]
Source: Biochimica et Biophysica Acta - Category: Biochemistry Authors: Tags: Biochim Biophys Acta Source Type: research

Related Links:

Condition:   Aging Intervention:   Drug: AAV-hTERT Sponsor:   Libella Gene Therapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Alzheimer Disease Intervention:   Drug: AAV-hTERT Sponsor:   Libella Gene Therapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CAMBRIDGE, Mass., Oct. 21, 2019 -- (Healthcare Sales &Marketing Network) -- SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today anno... Biopharmaceuticals, Personnel SmartPharm Therapeutics, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Cancer Gene Therapy, Published online: 21 October 2019; doi:10.1038/s41417-019-0146-2GATA3 suppresses human fibroblasts-induced metastasis of clear cell renal cell carcinoma via an anti-IL6/STAT3 mechanism
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
Cancer Gene Therapy, Published online: 21 October 2019; doi:10.1038/s41417-019-0144-4Application of RNA-sequencing to identify transcriptome modification by DCLK1 in colorectal cancer cells
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
Human Gene Therapy, Ahead of Print.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Source Type: research
.
Source: Expert Opinion on Biological Therapy - Category: Drugs & Pharmacology Authors: Source Type: research
Publication date: Available online 16 October 2019Source: Journal of Molecular LiquidsAuthor(s): Bernat Pi-Boleda, Mireia Bouzas, Nerea Gaztelumendi, Ona Illa, Carme Nogués, Vicenç Branchadell, Ramon Pons, Rosa M. OrtuñoAbstractChiral cis/trans diastereomeric cationic amphiphiles 8 and 9 have been synthesized and studied. They are based on β-amino acids and contain C12- and C16-alkyl chains, respectively, as hydrophobic tails while the polar head consists of an ammonium cation linked to a cyclobutane ring. Their physicochemical properties, such as the cmc (critical micellar concentration), the pKa...
Source: Journal of Molecular Liquids - Category: Molecular Biology Source Type: research
This article includes a brief history of how the senolytic suicide gene therapy company Oisin Biotechnologies came about. Oisin Biotechnologies was one of the first senolytics biotech startups, of which there are now many, one of the first longevity industry companies, and launched at a time in which it was still quite hard to persuade investors that treating aging as a medical condition was a legitimate line of work. That was actually just a few years ago now, 2015 as seen in the rear view mirror, and matters have changed rapidly since then. At the present time there are perhaps 50 to 100 startup biotech companies that we...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Abstract Virus vectors have been employed as gene transfer vehicles for various preclinical and clinical gene therapy applications and with the approval of Glybera (Alipogene tiparvovec) as the first gene therapy product as a standard medical treatment (Yla-Herttuala, Mol Ther 20:1831-1832, 2013), gene therapy has reached the status of being a part of standard patient care. Replication-competent herpes simplex virus (HSV) vectors that replicate specifically in actively dividing tumor cells have been used in Phase I-III human trials in patients with glioblastoma multiforme (GBM), a fatal form of brain cancer, and i...
Source: Herpes - Category: Infectious Diseases Authors: Tags: Methods Mol Biol Source Type: research
More News: Biochemistry | Gene Therapy | Genetics | Nanotechnology | Study